Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Metadata referenced "Palisade Bio," but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Neuralstem is a pre-clinical stage biotechnology company focused on developing human neural stem cell therapies for neurodegenerative conditions. The company has no commercial product revenue and relies on external financing and grants. As of March 31, 2009, the company had 33,751,300 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | $905,678 | $(2,274,452) |
| Operating Loss | $(2,912,044) | $(2,295,769) |
| Cash and Cash Equivalents (End of Period) | $3,567,108 | $8,257,850 |
| Net Cash Used in Operating Activities | $(1,296,966) | $(1,688,194) |
| Total Assets | $4,122,611 | $5,468,733 |
| Total Liabilities | $4,393,277 | $1,265,488 |
| Stockholders' Equity (Deficit) | $(270,666) | $4,203,245 |
Debt and Liquidity: The company reported no traditional debt but recognized a long-term liability of $2,762,835 related to the fair value of warrant obligations. The company estimates a monthly cash burn rate of approximately $500,000, with sufficient cash to fund operations for at least 9 months from the reporting date.
Material Changes vs. Prior Period
- Net Income vs. Loss: The company reported a net income of $905,678 in Q1 2009 compared to a net loss of $2,274,452 in Q1 2008. This reversal was driven entirely by a non-cash gain of $3,815,458 from the change in fair value of warrant obligations, offsetting an operating loss of $2,912,044.
- Equity Reclassification: Effective January 1, 2009, the company adopted EITF 07-05, reclassifying 8,547,762 warrants from equity to liability status. This resulted in a $6.9 million reduction in Additional Paid-in Capital and a $6.6 million establishment of warrant liabilities, causing stockholders' equity to shift from a surplus of $4.2 million in 2008 to a deficit of $270,666 in 2009.
- Operating Expenses: Total operating expenses increased by 27% to $2.91 million. Research and Development (R&D) expenses rose 20% to $1.43 million, and General and Administrative (G&A) expenses rose 35% to $1.46 million, largely due to litigation costs and increased stock-based compensation.
- Cash Position: Cash and cash equivalents decreased by 57% year-over-year, primarily due to the absence of equity financing in Q1 2009 (compared to $2.57 million raised in Q1 2008) and continued operational cash burn.
Guidance, Outlook, and Risks
Outlook and Guidance: Management does not anticipate any revenue for 2009. The company expects R&D and G&A expenses to increase as it transitions from pre-clinical to clinical phases. Management believes current cash levels are sufficient for approximately 9 months of operations, though certain activities may need reduction. If the FDA approves the Investigational New Drug (IND) application, the company estimates an additional $350,000 in costs for the trial.
Management Commentary: The company filed its first IND for an ALS clinical trial in December 2008. However, on February 20, 2009, the FDA placed the trial on clinical hold pending protocol modifications. The company is currently analyzing FDA comments.
Risks and Contingencies:
- Regulatory Risk: The clinical trial for ALS is on hold. There is no assurance the FDA will approve the IND or that future trials will succeed.
- Liquidity Risk: The company has a history of losses and requires significant additional capital to continue operations. Failure to secure financing could force delays or elimination of research programs.
- Listing Risk: Due to the reclassification of warrants to liabilities, stockholders' equity is negative. Management notes this may cause the company to fail to meet the continued listing requirements of the NYSE AMEX, potentially resulting in delisting.
- Legal Proceedings: The company is engaged in patent litigation with StemCells, Inc. regarding the validity and infringement of stem cell patents. The outcome is uncertain and could be costly.
Investor Verification Checklist
- Warrant Liability Impact: Verify the implications of the EITF 07-05 reclassification on the company's balance sheet and potential delisting from the NYSE AMEX due to negative stockholders' equity.
- Cash Runway: Confirm the current cash burn rate and the timeline for the next required financing round, given the 9-month runway estimate.
- IND Status: Monitor the status of the FDA clinical hold on the ALS trial and the timeline for resubmission of the protocol.
- Legal Exposure: Review the status of the patent litigation with StemCells, Inc. and potential financial exposure.
- Revenue Timeline: Acknowledge that the company expects zero revenue in 2009 and has no commercial products; profitability is not expected in the near term.